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Abstract Several approaches have been used to identify the
factors involved in mRNA splicing. None of them, however,
comprises a straightforward reversible method for inhibiting
the second step of splicing using an external reagent other
than a chelator. This investigation demonstrates that the addi-
tion of boric acid to an in vitro pre-mRNA splicing reaction
causes a dose-dependent reversible inhibition e¡ect on the sec-
ond step of splicing. The mechanism of action does not involve
chelation of several metal ions; hindrance of 3P splice-site; or
binding to hSlu7. This study presents a novel method for speci¢c
reversible inhibition of the second step of pre-mRNA splicing.
$ 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The spliceosome, a multicomponent complex of proteins
and RNA, is assembled on the newly synthesized precursor
messenger RNA (pre-mRNA) to catalyze a two-step transes-
teri¢cation reaction required to remove the introns and ligate
the exons (reviewed in [1]). The assembly of the spliceosome
proceeds through a coordinated assembly of complexes (rep-
resented by the letters E, A, B, C and I) or, alternatively, as
recently reported, through a one-step assembly [2^4]. More
than 140 proteins are involved in the splicing reaction [5],
some 15 of which are associated with puri¢ed complex C in
which splicing is arrested after the ¢rst step [6]. Currently, six
proteins have been found necessary for the second step of
splicing in yeast, and their human homologs have been iden-
ti¢ed (reviewed in [5]). The involvement of these and other
factors in the second step is still far from understood.
The present study is an in vitro investigation of the e¡ects
of boric acid on pre-mRNA splicing. Humans are exposed to
high concentrations of boric acid through pesticides, cosmet-
ics and medicines [7^9]. At high consumption boric acid is
toxic to all species through the reproductive and developmen-
tal systems [7], though it is not carcinogenic or mutagenic [10].
Boric acid does not appear to be metabolized in humans or
animals [11] and at low consumption it is reported to aid in
wound healing possibly by increasing RNA synthesis of tumor
necrosis factor K [12], vascular endothelial growth factor and
transforming growth factor L [13]. Recent studies suggest that
men who consume high levels of boron (found in fruits and
nuts) reduce their risk of prostate cancer [14] possibly by
enzymatic inhibition [15]. Borates can form a reversible bo-
rate^ester complex through intramolecular hydrogen bonding
at the nucleoside sugars’ cis-2P,3P-diol, which can interfere
with base pairing interactions [16]. In addition, borates can
disrupt protein activities [17] using two possible reversible
mechanisms; the ¢rst involves a covalent boronic acid tetra-
hedral adduct formed with the serine oxygen at the active site
of the enzyme that mimics a high-energy transition state struc-
ture [18] ; the second involves inhibition of metalloenzymes by
binding to metal ions in active sites and forming a stable
transition state analog [19].
We demonstrate that the addition of boric acid to an in
vitro mRNA splicing reaction e⁄ciently and speci¢cally inhib-
its the second step of splicing, and is accompanied by the
buildup of active spliceosomes paused before completion of
step two of the splicing reaction. The e¡ect of boric acid is
reversible and is probably induced by the attachment of three
oxygen atoms to the boron atom. We conclude that the mech-
anism of action does not involve the chelation of several metal
ions; hindrance of the 3P splice site (SS); or binding to a
second step splicing metalloprotein, hSlu7. This study presents
a novel method for speci¢c reversible inhibition of the second
step of pre-mRNA splicing.
2. Materials and methods
2.1. Splicing substrates, reactions, and spliceosome complex analysis
Standard splicing reactions were performed as described [20].
Brie£y, uniformly labeled RNA transcript was incubated in in vitro
splicing conditions with the addition of boric acid, butylboronic acid,
methylboronic acid, 3-aminophenylboronic acid, borax (sodium bo-
rate) and trimethyl borate, all brought to pH 7.9. To some of the
reactions divalent metal cations were added while to others recombi-
nant hSlu7 protein was added (see below). RNA was extracted and
analyzed by 8% denaturing polyacrylamide gel electrophoresis as de-
scribed [21]. Spliceosome complexes were analyzed in 4% native gels
as described [22] (with 0.5 mg/ml heparin in the loading bu¡er). The
dialysis procedure was performed as described [20].
2.2. Recombinant hSlu7 puri¢cation
The hSlu7 cDNA was provided by R. Reed and cloned into pGEX-
6P expression vector (Amersham-Pharmacia) fused upstream of the
glutathione S-transferase (GST) sequence. The recombinant hSlu7-
GST protein was expressed in Escherichia coli BL21 (DE3) strain
(Stratagene). Brie£y, following induction with 0.5 mM isopropyl-L-
D-thiogalactose for 6 h at 25‡C cells were lysed by sonication in lysis
bu¡er (phosphate-bu¡ered saline, 50 mM EDTA, 1% Triton), cell
debris was removed by centrifugation, and hSlu7-GST fused protein
was captured using glutathione Sepharose 4 Fast Flow as described by
the manufacturer (Amersham-Pharmacia). Recombinant protein was
puri¢ed to more than 95% homogeneity.
2.3. Site-speci¢c labeling of the pre-mRNA
Site-speci¢cally labeled pre-mRNA at position 31 of the 3P SS (the
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G nucleotide) was generated by transcribing two RNA templates: the
¢rst from the 5P exon to position 32 of the 3P SS (the A nucleotide),
and the second from position 31 of the 3P SS (the G nucleotide) to
the 3P exon. The 3P segment was dephosphorylated with 1 U of alka-
line phosphatase (Roche), end-labeled in a 20 Wl reaction mixture
containing 3.0 Wl of [Q-32P]ATP (3000 Ci/mmol), 2 U of T4 polynu-
cleotide kinase (New England Biolabs), and 4 Wl of the supplied bu¡er
from the same manufacturer. The 5P and 3P segments were ligated in a
20 Wl reaction mixture with a DNA oligonucleotide bridge spanning
both RNA fragments according to the manual (TaKaRa ligation kit).
The ligated product was separated in a 5% denaturing gel and ex-
tracted for further experiments.
3. Results
3.1. Boric acid inhibits the second step of splicing
To examine the e¡ect of boric acid on in vitro mRNA
splicing, HeLa nuclear extract was incubated under in vitro
conditions for 60 min with a labeled human L-globin tran-
script, the RNA was then extracted and separated in a dena-
turing gel. Addition of 5 mM boric acid led to an increase in
the amount of splicing intermediates and products (Fig. 1A,
compare lanes 1 and 2; an average two-fold increase in splic-
ing activity was quantitated in ¢ve di¡erent experiments; data
not shown; also see Section 4). However, only the products of
the second step of the splicing reaction decreased considerably
when 18 mM boric acid was added while ¢rst step products
were maintained at a high level (Fig. 1A, lane 4). An almost
complete inhibition of splicing was observed when 22 mM of
boric acid was added to the splicing reaction, followed by a
complete arrest of splicing activity at 26 mM (Fig. 1A, lanes 5
and 6, respectively). We concluded that the addition of 18
mM boric acid e⁄ciently and speci¢cally inhibited the second
step of splicing.
The inhibition of the second step of splicing by boric acid
was observed with six di¡erent nuclear extracts. The speci¢c
inhibiting concentration of boric acid di¡ered from one ex-
tract to the other but stayed within a 12^20-mM range (see
Fig. 3 for an additional example). The observation that di¡er-
ent nuclear extracts have di¡erent ranges of second step splic-
ing inhibition suggests that they harbor di¡erent concentra-
tions of an a¡ected factor(s). Thus, it is important to
individually titrate each nuclear extract in order to identify
its inhibitory concentration. Also, the second step splicing
inhibition by boric acid is a general phenomenon as ¢ve di¡er-
ent mRNA precursors exhibited a similar inhibition (data not
shown).
3.2. The e¡ect of boric acid on the spliceosome
To investigate the e¡ect of boric acid on spliceosome as-
sembly, we analyzed the complexes formed in the presence of
increasing boric acid concentrations. HeLa nuclear extract
was incubated with a radiolabeled L-globin transcript for 60
min under splicing conditions and the splicing reaction was
then separated in 4% native polyacrylamide gels (Fig. 2). In
the absence of boric acid, complex A was detected after 5 min
of incubation and declined thereafter. Complexes B and C
appeared after 5 min, reached a peak at 15 min, and declined
steadily thereafter. Thus, after 60 and 90 min of incubation A,
B and C complexes were barely detectable (see also [20,22]).
The addition of boric acid at 5 and 10 mM was accompa-
nied by increasing accumulation of complexes B/C (Fig. 2A,
lanes 2 and 3), reaching their peak at 18 mM (Fig. 2A, lane 4)
and declining thereafter at 22 and 26 mM (Fig. 2A, lanes 5
and 6). These complexes also were maintained even at longer
incubation periods (data not shown). The RNA content with-
in complexes B/C was determined showing ¢rst step splicing
intermediates only (data not shown; see also [20]). In the
absence of boric acid a newly identi¢ed complex, termed M,
was detected after 15 min incubation (Fig. 2B). This complex
contained RNA products of the second step of splicing evi-
denced by extraction of the RNA from complex M and anal-
ysis in a denaturing gel (Fig. 2C; also see Section 4). Panel D
is a quanti¢cation of complexes A and B/C as a function of
boric acid concentration, indicating the accumulation of ac-
tive spliceosomes (B/C) at 18 mM concentration. Thus, the
presence of boric acid at a range of concentrations that in-
hibits the second step of splicing was accompanied by buildup
of complexes B/C and inhibition of a unique complex M.
Fig. 1. Boric acid can e⁄ciently inhibit the second step of mRNA
splicing. A: A radiolabeled transcript of L-globin was incubated in
an in vitro splicing reaction. The indicated concentration of boric
acid (see Fig. 3A for chemical structure) was added to each reaction
and the reactions were incubated for 60 min at 30‡C. RNA was ex-
tracted and separated in an 8% denaturing gel. RNA intermediates
and products are schematically represented on the left. Exons are
drawn as boxes and introns as lines. A longer exposure of the free
5P exon is added below the main gel. B: Quanti¢cation of ¢rst
(circles) and second step (squares) splicing products presented in A.
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3.3. The inhibition is speci¢c to boric acid
The inhibition of the second step of splicing was speci¢c to
boron attached to three oxygen atoms since boronic acid com-
pounds, methyl- and butylboronic acid (see Fig. 3A for chem-
ical structures), did not inhibit splicing even at 22 and 30 mM
(Fig. 3B, compare BA to MBA and BBA). In addition, two
di¡erent boronic acid compounds that are known to dissoci-
ate to boric acid in aqueous solution, trimethyl borate and
borax, exhibited a similar inhibition to boric acid (data not
shown). 3-Aminophenylboronic acid (see Fig. 3A, APBA),
which binds cis-diol groups with high a⁄nity, inhibited the
¢rst step of splicing at 18 mM thus suggesting that it acts on
RNA itself, and strengthening the assumption that boric acid
exerts its e¡ect in a di¡erent manner. We could not exclude,
however, the formation of a boric ester complex with a ter-
minal ribose of the free 5P exon.
3.4. The inhibition e¡ect is reversible
To test whether the inhibitory e¡ect on the second step of
splicing is reversible we dialyzed the boric acid from the splic-
ing reaction. Splicing reactions were incubated for 60 min in
the absence or presence of 18 mM boric acid, and one part of
each reaction was removed while the other part was dialyzed
for 12 h against the nuclear extract bu¡er. The reactions were
then removed from the dialysis tube, a new set of co-factors
was added, and both the undialyzed and dialyzed reactions
were further incubated for 60 min (Fig. 4A, lanes 1^3 and 4^6,
respectively). The inhibition e¡ect on the second step of splic-
ing was reversible following 12 h dialysis (Fig. 4A, compare
lanes 2 and 5). When 26 mM boric acid was used there was
only a partial reversibility suggesting that at these concentra-
tions another factor(s) might be a¡ected by boric acid which is
not reversible after dialysis (one, for example, that binds co-
valently to boric acid; Fig. 4A, compare lanes 3 and 6).
We examined this further by showing that the splicing-in-
hibited reaction, dialyzed for not more than 3 h, restores only
the ¢rst step of splicing, even in the presence of an unlabeled
transcript competitor (at 500 times molar excess in order to
eliminate re-assembly of new spliceosomal complexes on the
labeled transcript following the dialysis [23,24] ; data not
shown).
This ¢nding further suggested that the inhibition of the
second step was not due to the interaction of boric acid
with the 3P end hydroxyl group of the ¢rst exon following
Fig. 2. The e¡ect of boric acid on the spliceosome. A: A radiolabeled L-globin transcript was incubated in nuclear extract under splicing condi-
tions in the presence of the indicated concentrations of boric acid. Splicing complexes were fractionated in a 4% non-denaturing gel and com-
plexes were identi¢ed according to their respective location on the gel and analysis of their labeled mRNA contents (data not shown). B: A
similar experiment was performed as described in A, but this time the reaction was carried out for 15 min. C: Analysis of the labeled mRNA
contents within complex M. Complex M, marked in panel B, was eluted from the gel and the labeled RNA was extracted and separated in 8%
denaturing gels. Unfractionated splicing reaction (Total) was run next to products extracted from complex M. RNA intermediates and products
are schematically represented to the right of the gel. There was no labeled RNA within the corresponding area of complex M in the reaction
incubated in the presence of boric acid (data not shown). D: Quanti¢cation of A (circles) and B/C (squares) complexes presented in panel A.
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the ¢rst step of splicing. Thus, we conclude that boric acid can
be used as an e⁄cient reagent to inhibit the second step of
splicing, and the inhibition can be reversed by a 12-h dialysis
process.
To eliminate the possibilities that we titrated splicing co-
factors or that boric acid interacted electrostatically with the
RNA, we added ATP, MgCl2, creatine phosphate and sucrose
(which has a 2P,3P-diol group) to the splicing-inhibited reac-
tion. The inhibition e¡ect could not be released by any of
these reagents suggesting that the inhibition e¡ect of boric
acid is not a simple interaction of the boric acid with the
diol groups on the ribose (as in [16,25^27]) nor a saturation
of the hydroxyl residues of boric acid (as in [28]).
3.5. The inhibition mechanism is not due to the chelation of Cu,
Mn, or Zn, binding to hSlu7 or 3P SS hindrance
There were indications that boric acid did not lead to for-
mation of non-functional spliceosomes: it did not interfere
with the normal assembly pathway of spliceosomal complexes
(A and B/C; Fig. 2) and splicing activity was restored follow-
ing the dialysis experiment, in particular in the presence of a
competitor (Fig. 4A and data not shown). To further test the
possibility that boric acid induces inter-spliceosomal interfer-
ence, we used a site-speci¢c 32P-labeled RNA transcript (at
position 31 of the 3P SS) that was incubated in in vitro splic-
ing conditions in the absence or presence of inhibitory boric
acid concentrations. Although no attempt was made to iden-
tify the crosslinked proteins, a comparison of those incubated
in the absence and presence of boric acid revealed no signi¢-
cant di¡erences (Fig. 4B). This implies that boric acid did not
induce a major interference in the binding of proteins to the 3P
SS. Moreover, there was no di¡erence in the binding of U1
and U2 snRNA to the 5P SS and branch site sequences, re-
spectively, as examined by crosslinking with psoralen (data
not shown).
We have previously shown that chelation of zinc from the
splicing reaction pauses splicing after the ¢rst step [20]. In
order to test whether boric acid and zinc function in a similar
manner, we performed an add-back reaction to try to reverse
the inhibitory e¡ect of boric acid. However, none of the di-
valent metal ions used in our experiments, copper, manganese
and zinc, was able to restore the inhibition of the second step,
suggesting that zinc and boric acid a¡ect mRNA splicing in
di¡erent manners (data not shown).
Currently, only one of the known second step splicing pro-
teins, hSlu7, contains a potential zinc knuckle domain and a
crosslinked protein with a similar molecular weight to hSlu7
(MW 68 kDa) was identi¢ed in that region [29]. The p68
crosslinked protein might be slightly a¡ected by incubation
in the presence of boric acid (Fig. 4B, indicated by an arrow).
We thus set out to determine whether addition of boric acid
disrupted hSlu7’s binding to the 3P SS. We reasoned that if
boric acid inhibits hSlu7’s function by binding to its metal
ion, addition of excess protein to the reaction (at almost equal
molar concentrations to the boric acid) will alleviate the inhi-
bition. However, puri¢ed recombinant hSlu7 (proved to be
active in mRNA splicing; data not shown) could not release
the inhibition, suggesting that hSlu7 is not the splicing factor
a¡ected by boric acid (data not shown).
4. Discussion
We have developed a simple method using boric acid to
speci¢cally and e⁄ciently inhibit the second step of mRNA
splicing. This inhibition is reversible upon prolonged dialysis,
and the inhibitory e¡ect requires the boron atom to be at-
Fig. 3. The e¡ect of various boronic acid compounds on splicing activity. A: The chemical structure of each compound used: BA, boric acid;
MBA, methylboronic acid; BBA, butylboronic acid; APBA, 3-aminophenylboronic acid. B: A radiolabeled L-globin transcript was incubated
in nuclear extract under standard splicing conditions in the presence of the indicated concentrations of the above reagents. Following 60 min
incubation at 30‡C, RNA was extracted and separated in an 8% denaturing gel.
FEBS 27616 11-9-03
N. Shomron, G. Ast/FEBS Letters 552 (2003) 219^224222
tached to three oxygen atoms. To the best of our knowledge,
this is the ¢rst mRNA splicing-related e¡ect associated with
borate. The inhibition of the second step of mRNA splicing
by boric acid can be used to identify the factors and the net-
work of interactions involved in this step. Given that inhibi-
tion concentrations ranged from 12 to 20 mM in our six
di¡erent nuclear extracts, it is recommended to titrate the
nuclear extract to identify its inhibitory concentration.
Our results indicate the resemblance between the unique M
complex, ¢rst identi¢ed here, located below complex H on the
native gel (Fig. 2B), and the 15S complex of the glycerol
gradient [30]. Analysis of complexes separated in the native
gels and mRNA products within this complex (Fig. 2C) led us
to conclude that the inhibition of the second splicing step
coincided with the accumulation of B/C complexes and inhi-
bition of complex M formation. It is worth noting that
L-globin pre-mRNA alone ran out of the native gel at these
conditions, and that the snRNPs ran above complex M, ex-
cept for U1 which ran at the bottom of the gel due to the
treatment of the splicing reaction with heparin (data not
shown). This suggests that complex M represents RNA prod-
ucts assembled with proteins and without snRNPs. However,
we cannot distinguish at this point whether the mRNA and
the intron lariat within the M complex are two di¡erent com-
plexes that co-migrate, or the same complex.
It is intriguing that the inhibitory e¡ect of boric acid on the
splicing reaction commences at millimolar concentrations,
which is greatly in excess of the spliceosomal component’s
concentration [31]. Nevertheless, this inhibition is rather spe-
ci¢c since boronic acid compounds without a three-hydroxyl
group surrounding the boron atom eliminated the inhibitory
e¡ect. Similarly, speci¢c inhibitions of enzymatic reactions by
borates at concentrations between 10 and 50 mM have been
demonstrated elsewhere [15,32^35]. Alternatively, if boric acid
interacts with many factors in the nuclear extract, higher con-
centrations are required to a¡ect the factor(s) involved in the
second step of splicing.
The hSlu7 protein is currently the only known metallopro-
tein involved solely in the second step of splicing, yet we
cannot exclude that other splicing metalloproteins were af-
fected by the addition of boric acid. This argument is sup-
ported, at least at the 26 mM concentration, by its partial
reversibility following dialysis.
At low concentrations of boric acid, usually 5^10 mM, an
increase in splicing activity is observed. It was previously re-
ported that 10 mM boric acid increases in vitro RNA syn-
thesis by more than 10-fold [13]. The increase in splicing in
our experiments is more of a general phenomenon and acts on
all transcripts tested. We cannot exclude that during in vitro
splicing boric acid protects the RNA from degradation. It is
recommended that 5 mM of boric acid be added to the splic-
ing in vitro reaction to improve splicing activity.
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